<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335137</url>
  </required_header>
  <id_info>
    <org_study_id>13-275</org_study_id>
    <nct_id>NCT03335137</nct_id>
  </id_info>
  <brief_title>Determining Drug Levels of Beta-lactam Antibiotics in Severe Burned Patients</brief_title>
  <acronym>MSBV</acronym>
  <official_title>Determining Drug Levels of Beta-lactam Antibiotics in Severe Burned Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Clinic III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dezernat Apotheke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At antibiotic stewardship of the University Hospital of Schleswig-Holsten it was noticed that
      there are much less studies measuring drug levels in severe burned patients than are
      required. Especially, severe burned patient developing a capillary leak might show lower drug
      levels than patients without a capillary leak. To compare drug levels of beta-lactam
      antibiotics, it is the aim of this study to measure pharmacokinetics of
      Piperacillin/Tazobactam in ICU patients with and without severe burns.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">May 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission</measure>
    <time_frame>1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission</time_frame>
    <description>Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Antibiotics</condition>
  <condition>Severe Burn</condition>
  <condition>Intensive Care</condition>
  <arm_group>
    <arm_group_label>ICU Patients with Severe Burns</arm_group_label>
    <description>Patients suffering from severe burns treated on a burn unit - Drug Level Monitoring Piperacillin/Tazobactam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICU Patients without Burns - Drug Level Monitoring</arm_group_label>
    <description>Patient suffering from disease treated on an ICU - Drug Level Monitoring Piperacillin/Tazobactam</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Drug Level Monitoring</intervention_name>
    <description>Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission</description>
    <arm_group_label>ICU Patients with Severe Burns</arm_group_label>
    <arm_group_label>ICU Patients without Burns - Drug Level Monitoring</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are used to determine drug levels of Piperacillin/Tazobactam
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated on ICU, in group 1 suffering from severe burns, in group 2 without burns
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General

          -  Adult

          -  Receiving beta-lactam antibiotic Piperacillin/Tazobactam

          -  Antibiotic therapy of 3 or more days

          -  Given informed consent Group 1

          -  Severe Burn Group 2

          -  No Severe Burn

        Exclusion Criteria:

          -  Already in another Study

          -  No useful blood sample
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Mailänder, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Plastic and Reconstructive Surgery, Hand Surgery, Burn Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter Raasch, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute for experimental and clinical pharmacology and toxicology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Kisch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Plastic and Reconstructive Surgery, Hand Surgery, Burn Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Rafla K, Tredget EE. Infection control in the burn unit. Burns. 2011 Feb;37(1):5-15. doi: 10.1016/j.burns.2009.06.198. Epub 2010 Jun 18. Review.</citation>
    <PMID>20561750</PMID>
  </reference>
  <reference>
    <citation>Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol. 2011 Dec;12(12):2070-9. Review.</citation>
    <PMID>21554211</PMID>
  </reference>
  <reference>
    <citation>Blanchet B, Jullien V, Vinsonneau C, Tod M. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet. 2008;47(10):635-54. Review.</citation>
    <PMID>18783295</PMID>
  </reference>
  <reference>
    <citation>Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA. Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study. Ther Drug Monit. 2012 Apr;34(2):160-4. doi: 10.1097/FTD.0b013e31824981a6.</citation>
    <PMID>22406650</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Tobias Kisch</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

